Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Liability Evaluation of ALKS 5461
NCT02413281Phase 1Completed
- Sponsor
- Alkermes
- Start
- Mar 2015
- Primary completion
- Sep 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buprenorphine + samidorphan in major depressive disorder (MDD) (6 arms), sponsored by Alkermes. Primary endpoint: Abuse potential measured by visual analog scales (VAS). Started Mar 2015; status: completed.
02
Drugs
buprenorphine + samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02413281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413281.